Therapeutic strategies in childhood multiple sclerosis

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 4, 2010, Pages 217-228

  Ghezzi, Angelo ^a  

^a Centro Studi Sclerosi Multipla   (Italy)

Author keywords

adolescence; childhood; cyclophosphamide; glatiramer acetate; interferon beta; intravenous immunoglobulin; intravenous methylprednisolone; mitoxantrone; multiple sclerosis; natalizumab

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; FUMARIC ACID; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; LAQUINIMOD; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PLACEBO; RITUXIMAB; TERIFLUNOMIDE;

ALOPECIA; AMENORRHEA; ANEMIA; ARTHRALGIA; BLADDER CANCER; BLOOD CELL COUNT; BLOOD DISEASE; CARDIOMYOPATHY; CHILD; CHRONIC ARTHRITIS; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; FLUSHING; HAIR LOSS; HEADACHE; HEMATURIA; HUMAN; INFECTION; INFERTILITY; INJECTION SITE REACTION; LABORATORY TEST; LEUKEMIA; LYMPHOCYTOPENIA; MENSTRUATION DISORDER; MENTAL DISEASE; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NERVE DEGENERATION; OSTEOPOROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; THORAX PAIN; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT FAILURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING;

EID: 77954912129     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285610371251     Document Type: Review

References (90)

1. Amato, M., Goretti, B., Ghezzi, A., Lori, S., Zipoli, V., Portaccio, E. et al. (2008) Cognitive and psychosocial features of childhood and juvenile MS. Neurology 70: 1891-1897.
2. Appleton, R.E. and Boggild, M. (2009) Natalizumab in paediatric multiple sclerosis and service implication. Dev Med Child Neurol 51: 758-759.
3. Banwell, B. ( 2005) Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurotherapeutics 5: 391-401.
4. Banwell, B.L. and Anderson, P.E. ( 2005) The cognitive burden of multiple sclerosis in children. Neurology 64: 891-894.
5. Banwell, B., Ghezzi, A., Bar-Or, A., Mikaeloff, Y. and Tardieu, M. ( 2007) Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 6: 887-902.
6. Banwell, B., Reder, A.T., Krupp, L., Tenembaum, S., Eraksoy, M., Alexey, B. et al. (2006) Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 66: 472-476.
7. Barnes, D., Hughes, R.A., Morris, R.W., Wade-Jones, O., Brown, P., Britton, T. et al. (1997) Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 349: 902-906.
8. Bar-Or, A., Calabresi, P.A., Arnold, D., Markowitz, C., Shafer, S., Kasper, L.H. et al. (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63: 395-400.
9. Bielekova, B., Howard, T., Packer, A.N., Richert, N., Blevins, G., Ohayon, J. et al. (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66: 483-489.
10. Boiko, A., Vorobeychik, G., Paty, D., Devonshire, V., Sadovnick, D. and the UBC MS Clinic Neurologists. (2002) Early onset multiple sclerosis: a longitudinal study. Neurology 59: 1006-1010.
11. Boriell, G., Prosperino, L., Lucchetti, A. and Pozzilli, C. (2009) Natalizumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 13: 67-71.
12. Capobianco, M., Rizzo, A., Malucchi, S., Sperli, F., Di Sapio, A., Oggero, A. et al. (2008) Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients. Neurol Sci 29: S227-S229.
13. Carson, K.R., Focosi, D., Major, E.O., Petrini, M., Richey, E.A., West, D.P. et al. (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10: 816-824.
14. Chabas, D., Castello-Trivino, T., Mowry, E.M., Strober, J.B., Glenn, O.A. and Waubant, E. ( 2008) Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype. Neurology 71: 1090-1093.
15. Cohen, J., Barkhof, F., Comi, G., Hartung, H.P., Khatri, B.O., Montalban, X. et al. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362: 402-415.
16. Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O. et al. (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357: 1576-1582.
17. Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A. et al. (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet Neurol 374: 1503-1511.
18. Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A. et al. (2008) Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre randomised double-blind placebo-controlled phase IIb study. Lancet 371: 2085-2092.
19. Compston, A. and Coles, A. ( 2002) Multiple sclerosis. Lancet 359: 1221-1231.
20. Ellis, R. and Boggild, M. (2009) Therapy related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler 15: 505-508.
21. Elovaara, I., Apostolski, S., van Doorn, P., Apostolski, S., van Dororn, P., Gilhus, N.E. et al. (2008) EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological disorders. Eur J Neurol 15: 893-908.
22. Farrell, R., Kapoor, R., Leary, S., Rudge, P., Thompson, A. and Miller, D. ( 2008) Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler 14: 212-218.
23. Filippi, M., Rovaris, M., Inglese, M., Barkhof, F., de Stefano, N., Smith, S. et al. (2004) Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 364: 1489-1496.
24. Filippini, G., Munari, L., Incorvaia, B., Ebers, G.C., Polman, C., D'Amico, R. et al. (2003) Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 361: 545-552.
25. Fisher, J.S., Priore, R.L., Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M. et al. (2000) Neuropsychological effects of interferon-beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 48: 885-892.
26. Freedman, M.S., Patry, D.G., Grand'Maison, F., Myles, M.L., Paty, D.W., Selchen, D.H. et al. (2004) Treatment optimization in multiple sclerosis. Can J Neurol Sci 31: 157-168.
27. Gasperini, C. and Ruggieri, S. (2009) New oral drugs for multiple sclerosis. Neurol Sci (Suppl 2): S179-S183.
28. Ghezzi, A. ( 2005) Childhood-juvenile multiple sclerosis: clinical characteristics and treatment. Expert Rev Neurotherapeutics 5: 403-411.
29. Ghezzi, A., Amato, M.P., Annovazzi, P., Capobianco, M., Gallo, P., La Mantia, L. et al. (2009 a) Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience. Neurol Sci 30: 193-199.
30. Ghezzi, A., Amato, M.P., Capobianco, M., Gallo, P., Marrosu, G., Martinelli, V. et al. (2005) Disease modifying drugs in childhood-juvenile multiple sclerosis: results of the ITEMS (immunomodulatory treatment of early-onset MS) study group. Mult Scler 11: 420-424.
31. Ghezzi, A., Banwell, B., Boyko, A., Amato M.P., Anlar B., Blinkenberg M. et al. (2010) The management of MS in children: A European view, Mult. Scler. in press.
32. Ghezzi, A., Pozzilli, C., Brescia-Morra, V., Bortolon, F., Capra, R., Grimaldi, L. et al. (2009 b) Safety and effectiveness of natalizumab in paediatric multiple sclerosis: results of 17 patients. Mult Scler 15(Suppl 2): 774.
33. Ghezzi, A., Pozzilli, C., Liguori, M., Marrosu, M.G., Dilani, N., Milanese, C. et al. (2002) Prospective study of multiple sclerosis with early onset. Mult Scler 8: 115-118.
34. Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Soelberg Sørensen, P. et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362: 416-426.
35. Goodin, D.S., Frohman, E.M., Garmany, G.P., Halper, J., Likosky, W.H., Lublin, F.D. et al. (2002) Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58: 169-178.
36. Gorman, M.P., Healy, B.C., Polgar-Turcsanyi, M. and Chitnis, T. (2009) Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 66: 54-59.
37. Gusev, E., Boiko, A., Bikova, O., Maslova, O., Guseva, M., Boiko, S. et al. (2002) The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 104: 203-207.
38. Havrdova, E., Galetta, S., Hutchinson, M., Stefoski, D., Bates, D., Polman, C.H. et al. (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8: 254-260.
39. Hawker, K., O'Connor, P., Freedman, M.S., Calabresi, P.A., Antel, J., Simon, J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66: 460-471.
40. Huppke, P., Stark, W., Zurcher, C., Huppke, B., Brück, W. and Gärtner, J. ( 2008) Natalizumab use in pediatric multiple sclerosis. Arch Neurol 65: 1655-1658.
41. Hyams, J.S., Wilson, D.C., Thomas, A. et al. (2007) Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 44: 185-191.
42. Jacobs, L.D., Beck, R.W., Simon, J.H., Kinkel, R.P., Brownscheidle, C.M., Murray, T.J. et al. (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343: 898-904.
43. Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1996) Intramuscular interferon beta 1-a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 39: 285-294.
44. Johnson, K.P., Brooks, B.R., Cohen, J.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double- blind, placebo-controlled trial. Neurology 45: 1268-1276.
45. Kappos, L., Bates, D., Hartung, H.P., Havrdova, E., Miller, D., Polman, C.H. et al. (2007 a) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6: 431-441.
46. Kappos, L., Freedman, M.S., Polman, C., Edan, G., Hartung, H.P., Miller, D.H. et al. (2007 b) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis. Lancet Neurol 370: 389-397.
47. Kappos, L., Freedman, M., Polman, C.H., Edan, G., Hartung, H.P., Miller, D.H. et al. (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 11: 987-997.
48. Kappos, L., Gold, R., Miller, D.H., Macmanus, D.G., Havrdova, E., Limmroth, V. et al. (2008) Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre randomised double-blind placebo-controlled phase Iib study. Lancet 372: 1463-1472.
49. Kappos, L., Polman, C., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 67: 1242-1249.
50. Kappos, L., Radue, E.W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P. et al. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362: 387-401.
51. Karenfort, M., Kieseier, B.C., Tibussek, D., Assmann, B., Schaper, J. and Mayatepek, E. (2009) Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis. Dev Med Child Neurol 51: 159-161.
52. Kornek, B., Bernert, G., Balassy, C., Geldner, J., Prayer, D. and Feucht, M. ( 2003) Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis. Neuropediatrics 34: 120-126.
53. Lehmann, H.C., Hartung, H.P., Hetzel, G.R., Stüve, O. and Kieseier, B.C. ( 2006) Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders. Arch Neurol 63: 930-935.
54. MacAllister, W.S., Belman, A.L., Milazzo, M., Weisbrot, D.M., Christodoulou, C., Scherl, W.F. et al. (2005) Cognitive functioning in children and adolescents with multiple sclerosis. Neurology 64: 1422-1425.
55. Makhani, N., Gorman, M.P., Branson, H.M., Stazzone, L., Banwell, B.L. and Chitnis, T. (2009) Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 72: 2076-2082.
56. Malucchi, S., Gilli, F., Caldano, M., Marnetto, F., Valentino, P., Granieri, L. et al. (2008) Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 70: 1119-1127.
57. Martinelli, V., Capra, R. and Cocco, E. (2009) High incidence of acute leucemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study. Mult Scler (Suppl 2): S167-S170.
58. Mikaeloff, Y., Caridde, G., Tardieu, M. and Suissa, S. ( 2008) Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative study. Eur J Paediatr Neurol 12: 205-209.
59. Mikaeloff, Y., Moreau, T., Debouverie, M., Pelletier, J., Lebrun, C., Gout, O. et al. (2001) Interferon-beta treatment in patients with childhood-onset multiple sclerosis. J Pediatr 139: 443-446.
60. Morrow, S.A., Stoian, C.A., Dmitrovic, J., Chan, S.C. and Metz, L.M. ( 2004) The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis. Neurology 63: 1079-1080.
61. O'Connor, P.W., Freedman, M.S., Bar-Or, A., Rice, G.P., Confavreux, C., Paty, D.W. et al. (2006) A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 66: 894-900.
62. Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. Neurology 49: 1404-1413.
63. Pakdaman, H., Fallah, A., Sahraian, M.A., Pakdaman, R. and Meysamie, A. ( 2006) Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. Neuropediatrics 37: 257-260.
64. Patti, F., Amato, M.P., Bastianello, S., Caniatti, L., Di Monte, E., Ferrazza, P. et al. (2010) Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 16: 68-77.
65. Pohl, D., Rostasy, K., Gartner, J. and Hanefeld, F. ( 2005) Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a. Neurology 65: 888-890.
66. Pohl, D., Rostasy, K., Reiber, H. and Hanefeld, F. ( 2004) CSF characteristics in early-onset multiple sclerosis. Neurology 63: 1966-1967.
67. Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 354: 899-910.
68. Portaccio, E., Zipoli, V., Siracusa, G., Sorbi, S. and Amato, M.P. ( 2006) Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria. Mult Scler 12: 281-286.
69. PRISM Study Group (1998) Randomized double-blind placebo controlled study of interferon beta 1-a in relapsing-remitting multiple sclerosis. Lancet 352: 1498-1504.
70. Renoux, C., Vukusic, S., Mikaeloff, Y., Mikaeloff, Y., Edan, G., Clanet, M. et al. (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 365: 2603-2613.
71. Rio, J., Castello, J., Rovira, A., Tintoré, M., Sastre-Garriga, J., Horga, A. et al. (2009) Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 15: 848-853.
72. Rio, J., Nos, C., Tintorè, M., Téllez, N., Galán, I., Pelayo, R. et al. (2006) Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 59: 344-352.
73. Rio, J., Rovira, A., Tintoré, M., Huerga, E., Nos, C., Tellez, N. et al. (2008) Relationship between MRI lesion activity and response to IFNβ in relapsing remitting multiple sclerosis patients. Mult Scler 14: 479-484.
74. Rudick, R., Lee, J., Simon, J., Ransohoff, R.M. and Fisher, E. ( 2004) Defining interferonβ response status in multiple sclerosis. Ann Neurol 56: 548-555.
75. Sørensen, P.S., Deisenhammer, F., Duda, P., Hohlfeld, R., Myhr, K.M., Palace, J. et al. (2005) Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 12: 817-827.
76. Sørensen, P.S., Tscherning, T., Mathiesen, H.K., Langkilde, A.R., Ross, C., Ravnborg, M. et al. (2006) Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 67: 1681-1683.
77. Soriani, M.P., Bonzano, L., Roccatagliata, L., Cutter, G.R., Mancardi, G.L., Bruzzi, P. et al. (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis. A meta-analytic approach. Ann Neurol 65: 268-275.
78. Takahashi, I., Sawaishi, Y., Takeda, O., Enoki, M. and Takada, G. ( 1997) Childhood multiple sclerosis treated with plasmapheresis. Pediatr Neurol 17: 83-87.
79. Tenembaum, S.N. and Segura, M.J. ( 2006) Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis. Neurology 67: 511-513.
80. The CAMMS 223 Trial Investigators (2008) Alentuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359: 1786-1801.
81. The IFNB Multiple Sclerosis Study Group (1993 ) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I clinical results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 43: 655-661.
82. The IFNB Multiple Sclerosis Study Group and the UBC M.S./MRI Analysis Group (1995) Interferon beta-1b in the treatment of MS: final outcome of the randomised controlled trial. Neurology 53: 1277-1285.
83. Tomassini, V., Paolillo, A., Russo, P., Giugni, E., Prosperini, L., Gasperini, C. et al. (2006) Predictors of long-term clinical response to interferon β therapy in relapsing multiple sclerosis. J Neurol 253: 287-293.
84. Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., Zipoli, V., Zimatore, G.B. et al. (2007) New natural history of interferon-beta treated relapsing multiple sclerosis. Ann Neurol 61: 300-306.
85. Trojano, M., Pellegrini, F., Fuiani, A., Paolicelli, D., Zimatore, G.B., Tortorella, C. et al. (2009) Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 66: 513-520.
86. Waubant, E., Chabas, D., Okuda, D., Glenn, O., Mowry, E., Henry, R.G. et al. (2009) Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 66: 967-971.
87. Waubant, E., Hietpas, J., Stewart, T., Dyme, Z., Herbert, J., Lacy, J. et al. (2001) Interferon beta-1a in children with multiple sclerosis is well tolerated. Neuropediatrics 32: 211-213.
88. Weinshenker, B.G., O'Brien, P.C., Petterson, T.M., Noseworthy, J.H., Lucchinetti, C.F., Dodick, D.W. et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46: 878-886.
89. Yousry, T.A., Major, E.O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J. et al. (2006) Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354: 924-933.
90. Zivadinov, R., Rudick, R.A., de Masi., Nasuelli, D., Ukmar, M., Pozzi-Mucelli, R.S. et al. (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57: 1239-1247.